Autres langues Zevra Therapeutics, Inc.

Actions

ZVRA

US4884452065

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
4,81 ^USD	+1,26%		+6,42%	-26,56%

28/03	Zevra Therapeutics, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
28/03	Transcript : Zevra Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024	01/05
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024	29/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	28/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	20/04
Zevra Therapeutics Metabolic Disorder Treatment Shows 'Meaningful Slowing of Disease Progression'	15/04
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting	15/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	12/04
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility	10/04
Zevra Therapeutics, Inc. Refinances Existing Debt with up to $100 million in Committed Capital under New Credit Facility	10/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	05/04
Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Posts Q4 Revenue $13.2M, vs. Street Est of $11.7M	28/03
Zevra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	28/03
Zevra Therapeutics Says Phase 2 Trial of Idiopathic Hypersomnia Treatment Fulfilled Objectives	27/03
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia	26/03
Zevra Therapeutics, Inc. Announces Top-Line Data from the Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia	26/03
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	25/03
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024	18/03
North American Morning Briefing : Inflation Data -2-	12/03
Sector Update: Health Care Stocks Mixed Late Afternoon	04/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Zevra Therapeutics, Inc.

Actions

ZVRA

US4884452065

Autres langues

Filtres